Status message

Active context: kki_bg_colors_yellow

A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC-34712) in Adolescents with Schizophrenia

Principal Investigator:

This is a phase 1, multicenter, open-label, dose-escalation trial in adolescent subjects (age 13 to 17 years) with a diagnosis of schizophrenia. This trial consists of a screening period (3 to 42 days, including washout of prohibited medications), a Dose Titration Phase, Fixed Dose Phase, and a safety follow-up.

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.